ESMO 2023: Highest risk patients with clear-cell renal cell carcinoma benefit from adjuvant everolimus
A secondary analysis from the SWOG S0931 EVEREST trial has found that in the subgroup…
Browsing: Featured Events
ESMO 2023: Adding immunotherapy to chemotherapy regimen improves survival in metastatic bladder cancer patients
A clinical trial co-led by Mount Sinai researchers is the first to show that using chemotherapy…
ESMO 2023: Kidney cancer study shows improved outcomes for patients with advanced disease when treated with belzutifan over everolimus
Belzutifan significantly reduced the risk of progression of clear cell renal cell carcinoma (ccRCC), the…
ESMO 2023: Air pollution and breast cancer risk – a link that calls for political action
Women living and working in places with higher levels of fine particle air pollution are…
ASTRO 2023: Sexual activity and vaginal dilation associated with fewer side effects after cervical cancer treatment
People who engage in sexual activity or vaginal dilation after chemoradiation treatment for cervical cancer…
The air we breathe: How air pollution microparticles are impacting cancer
One of the hot topics at the VCCC Alliance Research Conference was the role of…
ANZUP Cancer Trials Group Wraps Up Successful 2023 ASM
The Australian and New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group recently held another…
AGITG 25th Annual Scientific Meeting: Navigating a Path to Equity in GI Cancer Research
Q&A with Meeting Co-Convenor Dr Ben Lawrence, Head of Oncology at University of Auckland &…
AGITG 25th Annual Scientific Meeting: Navigating a Path to Equity in GI Cancer Research
Q&A with Meeting Co-Convenor Dr Ben Lawrence, Head of Oncology at University of Auckland &…
Novel theranostic agent targets multiple cancer types
A newly discovered radionuclide-based agent (CB-2PA-NT) has been shown to have high tumour uptake, sustained…